PT - JOURNAL ARTICLE AU - Sardinha, Daniele Melo AU - Lima, Karla Valéria Batista AU - da Silva Ferreira, Ana Lúcia AU - Garcez, Juliana Conceição Dias AU - Ueno, Thalyta Mariany Rêgo Lopes AU - Rodrigues, Yan Corrêa AU - dos Santos, Anderson Lineu Siqueira AU - de Loiola, Rosane do Socorro Pompeu AU - e Guimarães, Ricardo José de Paula Souza AU - Lima, Luana Nepomuceno Gondim Costa TI - Clinical and spatial characteristics of Severe Acute Respiratory Syndrome by COVID-19 in Indigenous of Brazil AID - 10.1101/2020.10.24.20218701 DP - 2021 Jan 01 TA - medRxiv PG - 2020.10.24.20218701 4099 - http://medrxiv.org/content/early/2021/06/09/2020.10.24.20218701.short 4100 - http://medrxiv.org/content/early/2021/06/09/2020.10.24.20218701.full AB - The new coronavirus (SARS-CoV-2) emerged in Wuhan in China in December 2019, causing severe pneumonias and deaths, soon in March 2020 it reached pandemic level, affecting several countries including Brazil. The disease was named COVID-19, with characteristics of most infected having mild and moderate symptoms and a part severe symptom. The disease has already reached 158 ethnic groups, which have high vulnerability and limited access to health services. The objective is to investigate the clinical and spatial characteristics of Severe Acute Respiratory Syndrome of COVID-19 in the indigenous peoples of Brazil. It is an epidemiological, cross-sectional, analytical ecological study, based on data from the OpenDataSUS platform from 01/01/2020 to 31/08/2020. Profile variables, signs and symptoms and risk factors/comorbidities. The data were analyzed by Bioestat 5.3. There were 1,207 cases and 470 deaths. Profile: male gender (59.48%) means age 53 years. Signs and symptoms: fever (74.23%), cough (77.71%), sore throat (35.62%), dyspnea (69.34%), respiratory discomfort (62.80%), O2 saturation <95% (56.42%); and associated with mortality: dyspnea (80.0%) and O2 saturation <95% (69.36%). Risk factors and comorbidities (45.89%) were associated with deaths (54.04%). Comorbidities: Chronic Cardiovascular Disease (18.97%) and Diabetes Mellitus (18.97%), and associated with deaths: Chronic Cardiovascular Disease (24.46%). Being admitted to the ICU has a risk of death in (OR-3.96-<0.0001-CI-2,913/5,383) followed by not being vaccinated against influenza (OR-1.85-<0.0001-CI-1,358/2,528). The public and health policies of Brazil should be directed to control the dissemination of COVID-19 in this population, that COVID-19 evolves in the same intensity, however, the indigenous have vulnerabilities that can increase the impact of the pan-demic in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) Coordenaccaoo de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:all authors have authorized the publicationAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are available on the opendatasus platform of the Brazilian Ministry of health